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P
atients with type 2 diabetes com-
pared with nondiabetic patients
have two- to ﬁvefold higher risk for
developing heart failure (1–3) and have
poorer outcomes once heart failure is
present (4,5). These relationships have
been identiﬁed in observational studies
spanning the clinical spectrum of diabe-
tes, including cohorts comprising pa-
tients with newly diagnosed type 2
diabetes (6), patients with or at high-risk
forcoronaryheartdisease(7,8),andthose
suffering acute coronary syndromes (9–
11). In the study by van Melle et al. (12)
published in this issue of Diabetes Care,
the relationship between diabetes and
heart failure risk among patients with sta-
ble coronary heart disease is again ob-
served. In addition, the observation is
made that higher A1C is linearly and in-
dependently associated with increased
heartfailurerisk,independentofwhether
the patient has established diabetes, with
the relationships qualitatively and quan-
titatively similar to prior reports (8,13).
Beforereviewingtheseobservationsinthe
context of the existing literature, a few
comments with regard to the study de-
sign, analyses, and interpretations of van
Melle et al. are warranted.
While the reported observations are
consistent with much of the existing liter-
ature associating disordered glucose me-
tabolism with incremental heart failure
risk,itmustbenotedthatthisstudyiden-
tiﬁed only 77 incident heart failure
events, including 30 among patients with
diabetes (15.0%) and 47 in those without
diabetes (7.4%). This small number of
eventslimitsthestatisticalpowerandpre-
cision of the analyses and calls for com-
mensuratecautionintheinterpretationof
the signiﬁcance and magnitude of the re-
ported associations. In addition, such a
small number of observed outcome
events limit the degrees of freedom in
multivariable models. Standard conven-
tion would limit the testing of 8–10 co-
variates at the most in a population with
77 events (i.e., the number of observed
events divided by 8–10) (14). In the ﬁnal
model presented, 18 covariates were in-
cluded (including diabetes status and
A1C measure), which runs the risk of
overﬁtting the data and thereby poten-
tially overestimating the magnitude and
signiﬁcance of observed associations. Fi-
nally, the failure to capture and analyze a
number of clinical factors that may inﬂu-
ence heart failure risk, especially those
unique to patients with diabetes (e.g.,
concomitant therapy with insulin and
thiazolidinediones, duration of diabetes,
distinction of type 1 vs. type 2 diabetes,
and concomitant microvascular disease,
among others), further challenges the in-
terpretation of the observations.
Beyond these methodological limita-
tions, one must also exercise caution in
interpreting the observed associations as
evidence of a causal link, as van Melle et
al. imply based on the association be-
tween increasing A1C and heart failure
risk. The present observations (as do any
observational analyses of association) fall
well short of providing proof of causality.
In fact, in the analyses limited to those
patients with medically treated diabetes,
no association was observed between
A1Candheartfailure,indirectlychalleng-
ing the hypothesis that modifying A1C
would alter the relationship along the
continuum of the association. This issue
has been recently demonstrated in the
negative trial results of three large-scale
randomizedtrialsofintensiveversusstan-
dard glucose control with regard to car-
diovascular risk mitigation (15–17). Each
of these trials was designed based on the
anticipated treatment effect of such inter-
ventions derived from epidemiological
modeling of the association between A1C
and atherosclerotic event rates, a method
that markedly overestimated the ob-
served magnitude of the treatment effect
observed (6). Thus, it remains entirely
unclear whether poor glycemic control is
a marker or a mediator (i.e., causative) of
adverse cardiovascular events like heart
failure.
Noting these limitations and assum-
ing the observations of van Melle et al. are
valid added to an extensive existing liter-
ature: what may we learn from such
ﬁndings? While the high prevalence of
concomitant morbidities known to
contribute to heart failure among pa-
tients with diabetes—principal among
them hypertension and coronary artery
disease—undoubtedlycontributetoin-
creased risk, several studies have dem-
onstrated that substantial heart failure
risk associated with diabetes remains
even after adjusting for these factors
(8,18). Incremental information in this
regard may be derived from the present
study by van Melle et al. (12) where dia-
betes remained powerfully and indepen-
dently associated with incident heart
failure risk even after adjusting for inter-
val ischemic events and the burden of
ischemiaderivedfromexercisestresstest-
ing, suggesting that other factors associ-
ated with diabetes likely contribute.
While the etiologic underpinnings of
the observed associations between diabe-
tes and heart failure risk beyond the ex-
cess burden of traditional risk factors
remain poorly understood, the potential
contributory role of a number of speciﬁc
metabolic perturbations occurring in the
setting of diabetes due to hyperglycemia,
insulin resistance, dysregulation of lipid
metabolism, perturbations of myocardial
substrate metabolism, cardiac steatosis,
aggregation of advanced glycation end
products, or a combination of these and
other metabolic insults continue to be the
fociofmanyscientiﬁcinvestigations(19–
21). Further understanding of these
mechanistic links may serve to better in-
form clinical decision-making by reﬁning
risk prediction and providing the patho-
physiological rationale for the use and
further study of existing therapeutic op-
tions and may accelerate new drug devel-
opmentinpursuitofnovelspeciﬁctargets
for pharmacological intervention.
The observed association between
higher A1C and increasing heart failure
risk, similar to previous published
associations of both fasting glucose and
A1C with incident heart failure risk
(13,22,23), is intriguing and is compati-
ble with the hypothesis that more inten-
sive glucose control may mitigate such
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from trials strongly refute this hypothesis
with no observed effect on heart failure in-
cidencewithmoreversuslessintensiveglu-
cose control observed across the three
recently reported cardiovascular outcome
trials comprising an aggregate total of al-
most 1,000 incident heart failure events
(15–17).Furthermore,somediabetesdrugs
mayhavedeleteriouseffectsindependentof
the degree of glucose control, such as the
well-known increase in heart failure risk
with thiazolidinediones (24), increased pe-
ripheraledemathatmaymimicheartfailure
withinsulinuse(25),andinhibitionofisch-
emic preconditioning with sulfonylurea
drugs (26,27). Conversely, other drugs
have been hypothesized to have salutary ef-
fects on cardiac function and heart failure
outcomes independent of glucose regula-
tionandmayyieldfavorableeffectsonheart
failure incidence and outcomes (28–30).
Theclinicalrelevanceoftheseobservations,
individually and in aggregate, remains
poorly understood.
As readers of Diabetes Care are cer-
tainly aware, the regulatory landscape for
the development of diabetes drugs has
undergone a major transformation over
the past 2 years (26,31). Approval of all
diabetes drugs will now require testing in
cohortsathighcardiovascularriskand,at
a minimum, the demonstration of cardio-
vascular safety; whether existing drugs
will have to undergo similar assessments
remains uncertain. Although the focus of
such regulatory guidance has been on the
effects of therapies on atherosclerotic vas-
cular disease risk, heart failure is a com-
mon comorbidity in these populations.
On this regulatory backdrop—and with
continuing advances in both clinical and
translational research—we are likely to
continue to evolve our understanding
with regard to the mechanistic links be-
tween diabetes, measures of glucose con-
trol, and heart failure; gain insight and
evidence with regard to the effects of glu-
cose control on heart failure risk; and de-
rive further information with regard to
speciﬁc diabetes therapies that may in-
ﬂuence cardiac performance and heart
failure risk independent of glucose
modulation. These possibilities under-
pin certain optimism for patients with di-
abetes who must live with the substantial
threat of developing heart failure and for
the clinicians who care for them.
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